Please assess the completion status of the following clinical trial:

Trial Title: Dextroamphetamine and tDCS to Improve the Fluency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18~* Native English proficiency;~* Nonfluent speech;~* Premorbid right handedness;~* Non-hemorrhagic left hemispheric stroke at least 6 months prior to the investigation.~* No contraindications for MRI (only subjects who will undergo MRI scan).~Exclusion Criteria:~* Hypersensitivity or idiosyncrasy to dextroamphetamine or to other sympathomimetic agents;~* Pregnant or trying to become pregnant;~* Active alcohol abuse, illicit drug use or drug abuse or significant mental illness;~* Subjects receiving alpha adrenergic antagonists or agonists;~* Any history of epilepsy;~* Any condition that would prevent the subject from giving voluntary informed consent;~* An implanted brain stimulator;~* Aneurysm clip or other metal in the brain;~* Enrolled or plans to enroll in an interventional trial during this study;~* Scalp wounds or infections;~* Previous stroke with residual deficits (TIAs not a reason for exclusion);~* A concurrent progressive neurologic disorder, acute coronary syndrome, severe heart disease (NYHA Classification \> 3), or other major medical condition;~* Advanced atherosclerosis, Unstable cardiac dysrhythmia or uncontrolled hypertension (\>160/100 mm Hg), or untreated hyperthyroidism;~* Diagnosis of glaucoma~* During or within 14 days following the administration of monoamine oxidase inhibitors;~* Subjects requiring palliative care;~* Terminal medical condition such as AIDS or cancer;~* Subjects unable to comprehend or follow verbal commands;~* Based on PI's or local physician's assessment patient unable to tolerate the trial procedure due to medical condition;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexedrine+sham tDCS+speech therapy (Type: EXPERIMENTAL): 10 mg Dexedrine and speech therapy for 10 days
- active tDCS+placebo+speech therapy (Type: EXPERIMENTAL): 1.5 mA anodal tDCS and speech therapy for 10 days
- Dexedrine+tDCS+speech therapy (Type: EXPERIMENTAL): 10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days
- sham stimulation+placebo+speech therapy (Type: EXPERIMENTAL): Sham stimulation, placebo and speech therapy for 10 days
- Dexedrine+tDCS+Speech Therapy (Type: EXPERIMENTAL): 10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
- placebo+tDCS+Speech Therapy (Type: EXPERIMENTAL): 1.5 mA anodal tDCS, and speech therapy for 1 day

Based on this trial design, predict the completion outcome and termination type (if applicable).